Head and neck squamous cell carcinoma (HNSCC) exhibits limited response to EGFR blockade with cetuximab, largely due to constant activation of the PI3K/AKT/mTOR pathways. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.